huperzine a has been researched along with Alzheimer Disease in 103 studies
huperzine A: RN given refers to 5R-(5alpha,9beta,11E)-isomer; structure given in first source
huperzine A : A sesquiterpene alkaloid isolated from a club moss Huperzia serrata that has been shown to exhibit neuroprotective activity. It is also an effective inhibitor of acetylcholinesterase and has attracted interest as a therapeutic candidate for Alzheimer's disease.
Alzheimer Disease: A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Huperzine A is a natural cholinesterase inhibitor derived from the Chinese herb Huperzia serrata that may compare favorably in symptomatic efficacy to cholinesterase inhibitors currently in use for Alzheimer disease (AD)." | 9.15 | A phase II trial of huperzine A in mild to moderate Alzheimer disease. ( Aisen, PS; Behan, K; Jin, S; Little, JT; Rafii, MS; Reynolds, B; Thomas, R; Walsh, S; Ward, C, 2011) |
| " An overview of systematic reviews (SRs) was conducted to summarize the findings of SRs and meta-analyses on the effectiveness of Huperzine A (Hup A) in dementia and mild cognitive impairment (MCI)." | 9.12 | The effects of Huperzine A on dementia and mild cognitive impairment: An overview of systematic reviews. ( Dehghani Ahmadabad, A; Ghassab-Abdollahi, N; Mirghafourvand, M; Mobasseri, K; Nadrian, H, 2021) |
| "To evaluate the clinical efficacy and safety of huperzine Alpha in treatment of patients with mild to moderate Alzheimer disease (AD)." | 9.10 | [Clinical efficacy and safety of huperzine Alpha in treatment of mild to moderate Alzheimer disease, a placebo-controlled, double-blind, randomized trial]. ( Chen, Q; Shan, G; Shu, L; Wang, J; Wang, X; Zhang, Z, 2002) |
| " We investigated the effects of the acetylcholinesterase inhibitor, huperzine A (Hup A), on APP processing and Abeta generation in human neuroblastoma SK-N-SH cells overexpressing wild-type human APP695." | 7.74 | Huperzine A regulates amyloid precursor protein processing via protein kinase C and mitogen-activated protein kinase pathways in neuroblastoma SK-N-SH cells over-expressing wild type human amyloid precursor protein 695. ( Jiang, L; Lee, DY; Lemere, CA; Ma, Z; Peng, Y; Schachter, SC, 2007) |
| "Alzheimer's disease is a worldwide metabolic disease and an economically costly disease to society, so more medicines need to be developed to treat this disease." | 5.39 | Quantitative proteomic analysis reveals the neuroprotective effects of huperzine A for amyloid beta treated neuroblastoma N2a cells. ( Fang, L; Jiang, H; Tao, Y; Yang, H; Yang, Y; Zhang, H; Zhou, H, 2013) |
| "Huperzine A is a natural cholinesterase inhibitor derived from the Chinese herb Huperzia serrata that may compare favorably in symptomatic efficacy to cholinesterase inhibitors currently in use for Alzheimer disease (AD)." | 5.15 | A phase II trial of huperzine A in mild to moderate Alzheimer disease. ( Aisen, PS; Behan, K; Jin, S; Little, JT; Rafii, MS; Reynolds, B; Thomas, R; Walsh, S; Ward, C, 2011) |
| " An overview of systematic reviews (SRs) was conducted to summarize the findings of SRs and meta-analyses on the effectiveness of Huperzine A (Hup A) in dementia and mild cognitive impairment (MCI)." | 5.12 | The effects of Huperzine A on dementia and mild cognitive impairment: An overview of systematic reviews. ( Dehghani Ahmadabad, A; Ghassab-Abdollahi, N; Mirghafourvand, M; Mobasseri, K; Nadrian, H, 2021) |
| "To evaluate the clinical efficacy and safety of huperzine Alpha in treatment of patients with mild to moderate Alzheimer disease (AD)." | 5.10 | [Clinical efficacy and safety of huperzine Alpha in treatment of mild to moderate Alzheimer disease, a placebo-controlled, double-blind, randomized trial]. ( Chen, Q; Shan, G; Shu, L; Wang, J; Wang, X; Zhang, Z, 2002) |
| " We investigated the effects of the acetylcholinesterase inhibitor, huperzine A (Hup A), on APP processing and Abeta generation in human neuroblastoma SK-N-SH cells overexpressing wild-type human APP695." | 3.74 | Huperzine A regulates amyloid precursor protein processing via protein kinase C and mitogen-activated protein kinase pathways in neuroblastoma SK-N-SH cells over-expressing wild type human amyloid precursor protein 695. ( Jiang, L; Lee, DY; Lemere, CA; Ma, Z; Peng, Y; Schachter, SC, 2007) |
| "Comparison of single and multiple dose pharmacokinetics between patches and conventional tablets of Huperzine A (Hup-A) was performed in beagle dogs to evaluate the patches' controlled drug release characteristics in vivo, a newly developed transdermal system for treatment of Alzheimer disease." | 3.74 | Pharmacokinetics of Huperzine A after transdermal and oral administration in beagle dogs. ( Chen, GS; Ye, JC; Zeng, S; Zheng, GL, 2008) |
| " Such products include 'qinghaosu' (artemisinin) and huperzine A, which are used in the treatment of malaria and Alzheimer's disease, respectively." | 3.73 | Editorial: natural products chemistry in China. ( Tan, RX, 2006) |
| "Huperzine A has been identified as a potent natural product against Alzheimer's disease." | 3.01 | Natural Products as Bioactive Agents in the Prevention of Dementia. ( Asif, M; Hussain, A; Nawaz, F; Rasool, M; Ullah, H, 2023) |
| "Huperzine A (Hup A) is a purified alkaloid compound extracted from a club moss called Huperzia serrata." | 2.82 | A Synopsis of Multitarget Potential Therapeutic Effects of Huperzine A in Diverse Pathologies-Emphasis on Alzheimer's Disease Pathogenesis. ( Govitrapong, P; Shukla, M; Wongchitrat, P, 2022) |
| "Huperzine A (HupA) is a plant-derived lycopodium alkaloid used for the treatment of Alzheimer's disease due to its inhibition against acetylcholinesterase." | 2.82 | Delineating biosynthesis of Huperzine A, A plant-derived medicine for the treatment of Alzheimer's disease. ( Li, W; Li, X; Tan, T; Tian, P, 2022) |
| " Pharmacokinetic parameters, including Cmax, AUC0-72 h and AUC0-∞ were calculated." | 2.78 | Phase I study on the pharmacokinetics and tolerance of ZT-1, a prodrug of huperzine A, for the treatment of Alzheimer's disease. ( Gui, YZ; Hong, Z; Jia, JY; Liu, GY; Liu, Y; Yu, C; Zhao, QH; Zhu, DY, 2013) |
| "Neurodegenerative disorders especially Alzheimer's disease (AD) are significantly threatening the public health." | 2.66 | Microbial acetylcholinesterase inhibitors for Alzheimer's therapy: recent trends on extraction, detection, irradiation-assisted production improvement and nano-structured drug delivery. ( Abd Elkodous, M; El-Sayed, ER; El-Sayyad, GS; Zaki, AG, 2020) |
| "The etiopathology of Alzheimer's disease (AD) is extremely complex and heterogeneous, often associated with comorbidities." | 2.49 | Multitarget drugs of plants origin acting on Alzheimer's disease. ( Cesario, A; Del Bufalo, A; Fini, M; Frustaci, A; Russo, P, 2013) |
| "Huperzine A is a Chinese herb extract used for Alzheimer's disease." | 2.49 | Huperzine A for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials. ( Liu, JP; Tian, J; Wang, Y; Yang, G, 2013) |
| " Most adverse events were cholinergic in nature and no serious adverse events occurred." | 2.45 | Efficacy and safety of natural acetylcholinesterase inhibitor huperzine A in the treatment of Alzheimer's disease: an updated meta-analysis. ( Chen, HZ; Song, YY; Wang, BS; Wang, H; Wei, ZH; Zhang, L, 2009) |
| "Huperzine A is a natural cholinesterase inhibitor derived from the Chinese herb Huperzia serrata." | 2.44 | An update on huperzine A as a treatment for Alzheimer's disease. ( Aisen, PS; Little, JT; Walsh, S, 2008) |
| "In order to advance the treatment of Alzheimer's disease with active ingredients of Chinese herbal medicines and the research on these ingredients and their effective targets in treating the disease, the relative representative literatures published in recent years were reviewed and summarized in this paper." | 2.44 | [Progress of study on treatment of Alzheimer's disease with active ingredients of Chinese herbal medicines]. ( Wang, DS; Zhao, JK, 2008) |
| "Huperzine A is a linearly competitive, reversible inhibitor of acetyl cholinesterase that is said to have both central and peripheral activity with the ability to protect cells against hydrogen peroxide, beta-amyloid protein (or peptide), glutamate, ischemia and staurosporine-induced cytotoxicity and apoptosis." | 2.44 | Huperzine A for Alzheimer's disease. ( Dong, BR; Li, J; Liu, GJ; Wu, HM; Zhou, RL, 2008) |
| "Huperzine A is a strong inhibitor of cholinesterases with high selectivity to acetylcholinesterase and in China is developed as therapeutic against Alzheimer's disease." | 2.40 | Huperzine A--an interesting anticholinesterase compound from the Chinese herbal medicine. ( Patocka, J, 1998) |
| "Huperzine A has been shown to be useful in the treatment of symptoms of dementia of the Alzheimer type." | 2.38 | Natural and synthetic Huperzine A: effect on cholinergic function in vitro and in vivo. ( Hanin, I; Kindel, GL; Kozikowski, AP; Tang, XC, 1993) |
| "Huperzine A (Hup A) is an important drug for treating Alzheimer's disease (AD) and mainly extracted from the Huperzia serrata (Thunb." | 1.56 | Five novel and highly efficient endophytic fungi isolated from Huperzia serrata expressing huperzine A for the treatment of Alzheimer's disease. ( Fei, L; Han, Z; Li-Bin, Y; Lu, H; Min, J; Ning, Z; Wei-Ze, L; Wen-Xia, H; Xiao-Feng, L; Zhong-Wen, H, 2020) |
| "Huperzine A (HupA) is a kind of Lycopodium alkaloid with potential disease-modifying qualities that has been reported to protect against β-amyloid (Aβ)-mediated mitochondrial damage in Alzheimer's disease." | 1.51 | ABAD/17β-HSD10 reduction contributes to the protective mechanism of huperzine a on the cerebral mitochondrial function in APP/PS1 mice. ( Chen, Q; Wang, Y; Xiao, X; Zhu, X, 2019) |
| "Huperzine A (HupA) is a selective acetylcholinesterase inhibitor used to treat Alzheimer's disease." | 1.51 | The Optimization Design Of Lactoferrin Loaded HupA Nanoemulsion For Targeted Drug Transport Via Intranasal Route. ( Ding, Z; Han, T; Jiang, Y; Liu, C; Zhai, W; Zhuang, N, 2019) |
| "Huperzine A treatment was shown to significantly attenuate the neurotoxicity of oligomeric Aβ(42), as demonstrated by increased neuronal viability." | 1.42 | Involvement of Intracellular and Mitochondrial Aβ in the Ameliorative Effects of Huperzine A against Oligomeric Aβ42-Induced Injury in Primary Rat Neurons. ( Jiang, HL; Lei, Y; Qin, MY; Tang, XC; Yang, HY; Yang, L; Ye, CY; Zhang, HY, 2015) |
| "serrata extract exerts any effects in Alzheimer's disease (AD) models." | 1.42 | Japanese Huperzia serrata extract and the constituent, huperzine A, ameliorate the scopolamine-induced cognitive impairment in mice. ( Abe, N; Hara, H; Ishisaka, M; Ohba, T; Oyama, M; Shimazawa, M; Tabira, T; Tsuruma, K; Yoshino, Y, 2015) |
| " Furthermore, subcutaneous administration of Bis-Mep (10, 100 or 1000 ng/kg) significantly reversed the scopolamine-induced memory deficits in a typical bell-shaped dose-response manner." | 1.39 | Bis(9)-(-)-nor-meptazinol as a novel dual-binding AChEI potently ameliorates scopolamine-induced cognitive deficits in mice. ( Chen, HZ; Cui, Y; Ge, XX; Li, J; Liu, T; Qiu, ZB; Wang, H; Xia, Z; Xie, Q; Xu, J; Xu, JR; Zhang, WW, 2013) |
| "Alzheimer's disease is a worldwide metabolic disease and an economically costly disease to society, so more medicines need to be developed to treat this disease." | 1.39 | Quantitative proteomic analysis reveals the neuroprotective effects of huperzine A for amyloid beta treated neuroblastoma N2a cells. ( Fang, L; Jiang, H; Tao, Y; Yang, H; Yang, Y; Zhang, H; Zhou, H, 2013) |
| "Huperzine A (HupA) is a reversible and selective inhibitor of acetylcholinesterase (AChE), and it has multiple targets when used for Alzheimer's disease (AD) therapy." | 1.37 | Huperzine A activates Wnt/β-catenin signaling and enhances the nonamyloidogenic pathway in an Alzheimer transgenic mouse model. ( Teng, WP; Wang, CY; Wang, SL; Wang, T; Wang, ZY; Xie, JW; Zhao, BL; Zheng, W, 2011) |
| "Muscle fasciculation appeared only after donepezil with a dose-dependent incidence and intensity." | 1.32 | Comparative effects of huperzine A, donepezil and rivastigmine on cortical acetylcholine level and acetylcholinesterase activity in rats. ( Liang, YQ; Tang, XC, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (8.74) | 18.2507 |
| 2000's | 45 (43.69) | 29.6817 |
| 2010's | 34 (33.01) | 24.3611 |
| 2020's | 15 (14.56) | 2.80 |
| Authors | Studies |
|---|---|
| Friedli, MJ | 1 |
| Inestrosa, NC | 1 |
| Shukla, M | 1 |
| Wongchitrat, P | 1 |
| Govitrapong, P | 1 |
| Villegas, C | 1 |
| Perez, R | 1 |
| Petiz, LL | 1 |
| Glaser, T | 1 |
| Ulrich, H | 1 |
| Paz, C | 1 |
| Ullah, H | 1 |
| Hussain, A | 1 |
| Asif, M | 1 |
| Nawaz, F | 1 |
| Rasool, M | 1 |
| Li, X | 2 |
| Li, W | 1 |
| Tian, P | 1 |
| Tan, T | 1 |
| Guo, Q | 1 |
| Cai, Q | 1 |
| Huang, F | 1 |
| Wei, Z | 1 |
| Wang, JZ | 1 |
| Zhang, B | 1 |
| Liu, R | 1 |
| Yang, Y | 2 |
| Wang, X | 3 |
| Li, HL | 1 |
| Yan, YP | 2 |
| Chen, JY | 2 |
| Lu, JH | 2 |
| Xu, JB | 1 |
| Miao, SX | 2 |
| Gao, F | 2 |
| Wan, LX | 2 |
| Jiang, Y | 2 |
| Liu, C | 1 |
| Zhai, W | 1 |
| Zhuang, N | 1 |
| Han, T | 1 |
| Ding, Z | 1 |
| Shih, CC | 1 |
| Chen, PY | 1 |
| Chen, MF | 1 |
| Lee, TJF | 1 |
| Yang, X | 1 |
| Wei, HM | 1 |
| Hu, GY | 5 |
| Zhao, J | 1 |
| Long, LN | 1 |
| Li, CJ | 1 |
| Zhao, ZJ | 1 |
| Zeng, HK | 1 |
| Nie, H | 2 |
| Zaki, AG | 1 |
| El-Sayed, ER | 1 |
| Abd Elkodous, M | 1 |
| El-Sayyad, GS | 1 |
| Lushchekina, SV | 1 |
| Masson, P | 1 |
| Wen-Xia, H | 1 |
| Zhong-Wen, H | 1 |
| Min, J | 1 |
| Han, Z | 1 |
| Wei-Ze, L | 1 |
| Li-Bin, Y | 1 |
| Fei, L | 1 |
| Lu, H | 1 |
| Ning, Z | 1 |
| Xiao-Feng, L | 1 |
| Ghassab-Abdollahi, N | 1 |
| Mobasseri, K | 1 |
| Dehghani Ahmadabad, A | 1 |
| Nadrian, H | 1 |
| Mirghafourvand, M | 1 |
| He, ZX | 1 |
| Zhou, XL | 1 |
| Turkseven, CH | 1 |
| Buyukakilli, B | 1 |
| Balli, E | 1 |
| Yetkin, D | 1 |
| Erdal, ME | 1 |
| Yilmaz, SG | 1 |
| Sahin, L | 1 |
| Meng, Q | 1 |
| Wang, A | 1 |
| Hua, H | 1 |
| Wang, Y | 7 |
| Mu, H | 1 |
| Wu, Z | 1 |
| Sun, K | 1 |
| Son, M | 1 |
| Park, C | 1 |
| Rampogu, S | 1 |
| Zeb, A | 1 |
| Lee, KW | 1 |
| Gul, A | 1 |
| Bakht, J | 1 |
| Mehmood, F | 1 |
| Xiao, X | 1 |
| Chen, Q | 2 |
| Zhu, X | 1 |
| Russo, P | 1 |
| Frustaci, A | 1 |
| Del Bufalo, A | 1 |
| Fini, M | 1 |
| Cesario, A | 1 |
| Tao, Y | 1 |
| Fang, L | 1 |
| Jiang, H | 2 |
| Yang, H | 2 |
| Zhang, H | 1 |
| Zhou, H | 1 |
| Bai, F | 1 |
| Xu, Y | 1 |
| Chen, J | 1 |
| Liu, Q | 2 |
| Gu, J | 1 |
| Ma, J | 1 |
| Li, H | 2 |
| Onuchic, JN | 1 |
| Zhang, L | 2 |
| Han, L | 1 |
| Qin, J | 1 |
| Lu, W | 1 |
| Wang, J | 2 |
| Jia, JY | 1 |
| Zhao, QH | 1 |
| Liu, Y | 1 |
| Gui, YZ | 1 |
| Liu, GY | 1 |
| Zhu, DY | 1 |
| Yu, C | 1 |
| Hong, Z | 1 |
| Yang, G | 1 |
| Tian, J | 1 |
| Liu, JP | 1 |
| Huang, XT | 2 |
| Qian, ZM | 1 |
| He, X | 1 |
| Gong, Q | 1 |
| Wu, KC | 1 |
| Jiang, LR | 1 |
| Lu, LN | 1 |
| Zhu, ZJ | 1 |
| Zhang, HY | 10 |
| Yung, WH | 1 |
| Ke, Y | 1 |
| Yan, R | 1 |
| Zhang, Z | 2 |
| Zeng, Q | 1 |
| Zhu, D | 2 |
| Chioua, M | 1 |
| Pérez, M | 1 |
| Bautista-Aguilera, OM | 1 |
| Yañez, M | 1 |
| López, MG | 1 |
| Romero, A | 1 |
| Cacabelos, R | 1 |
| de la Bellacasa, RP | 1 |
| Brogi, S | 1 |
| Butini, S | 1 |
| Borrell, JI | 1 |
| Marco-Contelles, J | 1 |
| Lei, Y | 1 |
| Yang, L | 3 |
| Ye, CY | 2 |
| Qin, MY | 1 |
| Yang, HY | 1 |
| Jiang, HL | 1 |
| Tang, XC | 16 |
| Ohba, T | 1 |
| Yoshino, Y | 1 |
| Ishisaka, M | 1 |
| Abe, N | 1 |
| Tsuruma, K | 1 |
| Shimazawa, M | 1 |
| Oyama, M | 1 |
| Tabira, T | 1 |
| Hara, H | 1 |
| Wang, ZY | 2 |
| Liu, JG | 1 |
| Yang, HM | 1 |
| Damar, U | 1 |
| Gersner, R | 1 |
| Johnstone, JT | 1 |
| Schachter, S | 1 |
| Rotenberg, A | 1 |
| Peng, L | 1 |
| Rong, Z | 1 |
| Wang, H | 3 |
| Shao, B | 1 |
| Kang, L | 1 |
| Qi, H | 1 |
| Chen, H | 1 |
| Ma, X | 2 |
| Gang, DR | 2 |
| Zheng, CY | 2 |
| Yan, H | 3 |
| Wang, ZF | 1 |
| Tang, LL | 1 |
| Gao, X | 2 |
| Wang, BS | 1 |
| Wei, ZH | 1 |
| Song, YY | 1 |
| Chen, HZ | 2 |
| Desilets, AR | 1 |
| Gickas, JJ | 1 |
| Dunican, KC | 1 |
| Wang, CY | 1 |
| Zheng, W | 1 |
| Wang, T | 1 |
| Xie, JW | 1 |
| Wang, SL | 1 |
| Zhao, BL | 1 |
| Teng, WP | 1 |
| Rafii, MS | 1 |
| Walsh, S | 2 |
| Little, JT | 2 |
| Behan, K | 1 |
| Reynolds, B | 1 |
| Ward, C | 1 |
| Jin, S | 1 |
| Thomas, R | 1 |
| Aisen, PS | 3 |
| Orhan, IE | 1 |
| Orhan, G | 1 |
| Gurkas, E | 1 |
| Ha, GT | 1 |
| Wong, RK | 1 |
| Zhang, Y | 1 |
| Shi, J | 1 |
| Cong, W | 1 |
| Luo, G | 1 |
| Pohanka, M | 1 |
| Zemek, F | 1 |
| Bandouchova, H | 1 |
| Pikula, J | 1 |
| Cummings, J | 1 |
| Schneider, LS | 1 |
| Ratia, M | 1 |
| Giménez-Llort, L | 1 |
| Camps, P | 5 |
| Muñoz-Torrero, D | 5 |
| Pérez, B | 1 |
| Clos, MV | 1 |
| Badia, A | 3 |
| Konrath, EL | 1 |
| Neves, BM | 1 |
| Passos, Cdos S | 1 |
| Lunardi, PS | 1 |
| Ortega, MG | 1 |
| Cabrera, JL | 1 |
| Gonçalves, CA | 1 |
| Henriques, AT | 1 |
| Liu, T | 1 |
| Xia, Z | 1 |
| Zhang, WW | 1 |
| Xu, JR | 1 |
| Ge, XX | 1 |
| Li, J | 2 |
| Cui, Y | 1 |
| Qiu, ZB | 1 |
| Xu, J | 1 |
| Xie, Q | 1 |
| Wang, Z | 1 |
| Zhao, W | 1 |
| Lu, J | 1 |
| Zhang, C | 1 |
| Lok, K | 1 |
| Shen, H | 1 |
| Xu, Z | 1 |
| Yin, M | 1 |
| Zhao, Y | 1 |
| Dou, J | 1 |
| Wu, T | 1 |
| Aisa, HA | 1 |
| Shu, L | 1 |
| Shan, G | 1 |
| Howes, MJ | 1 |
| Perry, NS | 1 |
| Houghton, PJ | 1 |
| Zangara, A | 1 |
| He, XC | 3 |
| Yu, GL | 1 |
| Bai, DL | 4 |
| Liang, YQ | 2 |
| Jordá, EG | 1 |
| Verdaguer, E | 1 |
| Jiménez, A | 1 |
| Canudas, AM | 1 |
| Rimbau, V | 1 |
| Camins, A | 1 |
| Pallàs, M | 1 |
| Wang, R | 3 |
| Liu, WH | 1 |
| Song, JL | 1 |
| Liu, K | 1 |
| Chu, DF | 1 |
| Li, YX | 1 |
| Fu, X | 1 |
| Ping, Q | 1 |
| Gao, Y | 1 |
| Lyketsos, CG | 1 |
| Colenda, CC | 1 |
| Beck, C | 1 |
| Blank, K | 1 |
| Doraiswamy, MP | 1 |
| Kalunian, DA | 1 |
| Yaffe, K | 1 |
| Sivaprakasam, K | 1 |
| Gao, P | 1 |
| Xu, H | 1 |
| Ding, P | 1 |
| Gao, Q | 1 |
| Sun, J | 1 |
| Chen, D | 1 |
| Tan, RX | 1 |
| Duysen, EG | 1 |
| Li, B | 1 |
| Darvesh, S | 1 |
| Lockridge, O | 1 |
| Cheng, XR | 1 |
| Zhou, WX | 1 |
| Zhang, YX | 1 |
| Tan, C | 1 |
| Xiao, P | 1 |
| Li, WM | 1 |
| Kan, KK | 1 |
| Carlier, PR | 1 |
| Pang, YP | 1 |
| Han, YF | 1 |
| Peng, Y | 1 |
| Lee, DY | 1 |
| Jiang, L | 1 |
| Ma, Z | 1 |
| Schachter, SC | 1 |
| Lemere, CA | 1 |
| Ye, JC | 1 |
| Zeng, S | 1 |
| Zheng, GL | 1 |
| Chen, GS | 1 |
| Zhao, JK | 1 |
| Wang, DS | 1 |
| Wu, HM | 1 |
| Zhou, RL | 1 |
| Liu, GJ | 1 |
| Dong, BR | 1 |
| Fink, DM | 1 |
| Bores, GM | 1 |
| Effland, RC | 1 |
| Huger, FP | 1 |
| Kurys, BE | 1 |
| Rush, DK | 1 |
| Selk, DE | 1 |
| Hanin, I | 1 |
| Kindel, GL | 1 |
| Kozikowski, AP | 2 |
| Xu, SS | 2 |
| Gao, ZX | 1 |
| Weng, Z | 1 |
| Du, ZM | 1 |
| Xu, WA | 2 |
| Yang, JS | 1 |
| Zhang, ML | 1 |
| Tong, ZH | 1 |
| Fang, YS | 1 |
| Chai, XS | 1 |
| Skolnick, AA | 1 |
| Baños, JE | 2 |
| Contreras, J | 1 |
| Görbig, DM | 1 |
| Simón, M | 1 |
| Vivas, NM | 2 |
| Patocka, J | 1 |
| Kaur, J | 1 |
| Zhang, MQ | 1 |
| Cai, ZY | 1 |
| Qu, ZW | 1 |
| Yang, RM | 1 |
| Cai, YL | 1 |
| Wang, GQ | 1 |
| Su, XQ | 1 |
| Zhong, XS | 1 |
| Cheng, RY | 1 |
| Li, JX | 1 |
| Feng, B | 1 |
| Mazurek, AA | 1 |
| Xiao, XQ | 2 |
| Zhang, YH | 2 |
| Chen, XQ | 2 |
| Yang, HH | 2 |
| Jin, GY | 1 |
| Morral, J | 1 |
| Barril, X | 1 |
| Orozco, M | 1 |
| Luque, FJ | 1 |
| Zhou, J | 1 |
| Fu, Y | 1 |
| Zhang, JM | 1 |
| Zhao, XY | 1 |
| Li, Y | 1 |
| Geib, SJ | 1 |
| Tückmantel, W | 1 |
| Calon, F | 1 |
| Lim, GP | 1 |
| Morihara, T | 1 |
| Yang, F | 1 |
| Ubeda, O | 1 |
| Salem, N | 1 |
| Frautschy, SA | 1 |
| Cole, GM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Antioxidant Effect of Treatment With Ginkgo Biloba L. Leaf Extract (IDN 5933) on DNA Cell Maintenance and Genomic Stability: A Randomised Study Versus Placebo[NCT03004508] | Phase 2 | 66 participants (Actual) | Interventional | 2015-07-31 | Active, not recruiting | ||
| The Effect of Traditional Chinese Medicine (VGH-AD1) on Patients With Alzheimer's Disease: A Double-blinded Randomized Placebo-controlled Cross-over Study[NCT04249869] | Phase 1/Phase 2 | 28 participants (Anticipated) | Interventional | 2020-02-01 | Not yet recruiting | ||
| A Multi-Center, Double-Blind, Placebo-Controlled Therapeutic Trial to Determine Whether Natural Huperzine A Improves Cognitive Function[NCT00083590] | Phase 2 | 150 participants (Anticipated) | Interventional | 2004-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
36 reviews available for huperzine a and Alzheimer Disease
| Article | Year |
|---|---|
Huperzine A and Its Neuroprotective Molecular Signaling in Alzheimer's Disease.
Topics: Acetylcholinesterase; Alkaloids; Alzheimer Disease; Animals; Cholinesterase Inhibitors; Humans; Hupe | 2021 |
A Synopsis of Multitarget Potential Therapeutic Effects of Huperzine A in Diverse Pathologies-Emphasis on Alzheimer's Disease Pathogenesis.
Topics: Alkaloids; Alzheimer Disease; Amyloid beta-Peptides; Humans; Sesquiterpenes | 2022 |
Ginkgolides and Huperzine A for complementary treatment of Alzheimer's disease.
Topics: Activities of Daily Living; Alkaloids; Alzheimer Disease; Ginkgolides; Humans; Neurodegenerative Dis | 2022 |
Natural Products as Bioactive Agents in the Prevention of Dementia.
Topics: Acetylcholinesterase; Alkaloids; Alzheimer Disease; Biological Products; Humans | 2023 |
Delineating biosynthesis of Huperzine A, A plant-derived medicine for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alkaloids; Alzheimer Disease; Huperzia; Sesquiterpenes | 2022 |
Disease-Modifying Activity of Huperzine A on Alzheimer's Disease: Evidence from Preclinical Studies on Rodent Models.
Topics: Alkaloids; Alzheimer Disease; Amyloid beta-Peptides; Animals; Cholinesterase Inhibitors; Rodentia; S | 2022 |
Disease-Modifying Activity of Huperzine A on Alzheimer's Disease: Evidence from Preclinical Studies on Rodent Models.
Topics: Alkaloids; Alzheimer Disease; Amyloid beta-Peptides; Animals; Cholinesterase Inhibitors; Rodentia; S | 2022 |
Disease-Modifying Activity of Huperzine A on Alzheimer's Disease: Evidence from Preclinical Studies on Rodent Models.
Topics: Alkaloids; Alzheimer Disease; Amyloid beta-Peptides; Animals; Cholinesterase Inhibitors; Rodentia; S | 2022 |
Disease-Modifying Activity of Huperzine A on Alzheimer's Disease: Evidence from Preclinical Studies on Rodent Models.
Topics: Alkaloids; Alzheimer Disease; Amyloid beta-Peptides; Animals; Cholinesterase Inhibitors; Rodentia; S | 2022 |
Microbial acetylcholinesterase inhibitors for Alzheimer's therapy: recent trends on extraction, detection, irradiation-assisted production improvement and nano-structured drug delivery.
Topics: Alkaloids; Alzheimer Disease; Animals; Bacteria; Cholinesterase Inhibitors; Drug Delivery Systems; F | 2020 |
Slow-binding inhibitors of acetylcholinesterase of medical interest.
Topics: Acetylcholinesterase; Alkaloids; Alzheimer Disease; Animals; Cholinesterase Inhibitors; Humans; Myas | 2020 |
The effects of Huperzine A on dementia and mild cognitive impairment: An overview of systematic reviews.
Topics: Activities of Daily Living; Alkaloids; Alzheimer Disease; Cognitive Dysfunction; Dementia; Humans; Q | 2021 |
Multitarget drugs of plants origin acting on Alzheimer's disease.
Topics: Alkaloids; Alzheimer Disease; Animals; Biological Products; Cholinesterase Inhibitors; Crocus; Drug | 2013 |
Huperzine A for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials.
Topics: Alkaloids; Alzheimer Disease; Humans; Placebos; Publication Bias; Randomized Controlled Trials as To | 2013 |
Pharmacological Effects of Active Components of Chinese Herbal Medicine in the Treatment of Alzheimer's Disease: A Review.
Topics: Abietanes; Alkaloids; Alzheimer Disease; Curcuma; Curcumin; Drugs, Chinese Herbal; Epimedium; Evodia | 2016 |
Potential therapeutic targets of huperzine A for Alzheimer's disease and vascular dementia.
Topics: Alkaloids; Alzheimer Disease; Amyloid beta-Protein Precursor; Dementia, Vascular; Humans; Sesquiterp | 2008 |
Efficacy and safety of natural acetylcholinesterase inhibitor huperzine A in the treatment of Alzheimer's disease: an updated meta-analysis.
Topics: Activities of Daily Living; Alkaloids; Alzheimer Disease; Cholinesterase Inhibitors; Humans; Psychia | 2009 |
Role of huperzine a in the treatment of Alzheimer's disease.
Topics: Alkaloids; Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Humans; Neuroprot | 2009 |
An overview on natural cholinesterase inhibitors--a multi-targeted drug class--and their mass production.
Topics: Alkaloids; Alzheimer Disease; Cholinesterase Inhibitors; Galantamine; Humans; Huperzia; Liliaceae; S | 2011 |
Huperzine a as potential treatment of Alzheimer's disease: an assessment on chemistry, pharmacology, and clinical studies.
Topics: Alkaloids; Alzheimer Disease; Animals; Cholinesterase Inhibitors; Clinical Trials as Topic; Humans; | 2011 |
Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease.
Topics: Alkaloids; Alzheimer Disease; Amino Acids; Animals; Cholinesterase Inhibitors; Dietary Supplements; | 2012 |
Tacrine-huperzine A hybrids (huprines): a new class of highly potent and selective acetylcholinesterase inhibitors of interest for the treatment of Alzheimer's disease.
Topics: Alkaloids; Alzheimer Disease; Cholinesterase Inhibitors; Drug Design; Humans; Models, Molecular; Mol | 2001 |
Plants with traditional uses and activities, relevant to the management of Alzheimer's disease and other cognitive disorders.
Topics: Alkaloids; Alzheimer Disease; Estrogens, Non-Steroidal; Galantamine; Humans; Isoflavones; Physostigm | 2003 |
The psychopharmacology of huperzine A: an alkaloid with cognitive enhancing and neuroprotective properties of interest in the treatment of Alzheimer's disease.
Topics: Alkaloids; Alzheimer Disease; Animals; Clinical Trials as Topic; Humans; Neuroprotective Agents; Noo | 2003 |
Huperzine A.
Topics: Alkaloids; Alzheimer Disease; Animals; Drugs, Investigational; Humans; Nootropic Agents; Sesquiterpe | 2004 |
Neuroprotective effects of huperzine A. A natural cholinesterase inhibitor for the treatment of Alzheimer's disease.
Topics: Alkaloids; Alzheimer Disease; Animals; Brain Chemistry; Cell Death; Cerebrovascular Disorders; Choli | 2005 |
Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine.
Topics: Alkaloids; Alzheimer Disease; Animals; Apoptosis; Brain; Cholinesterase Inhibitors; Cholinesterases; | 2006 |
Towards a unifying hypothesis of Alzheimer's disease: cholinergic system linked to plaques, tangles and neuroinflammation.
Topics: Alkaloids; Alzheimer Disease; Amyloid; Cholinergic Fibers; Cholinesterase Inhibitors; Galantamine; I | 2006 |
Huperzine A from Huperzia species--an ethnopharmacolgical review.
Topics: Alkaloids; Alzheimer Disease; China; Cholinesterase Inhibitors; Clinical Trials as Topic; Europe; Hu | 2007 |
Non-cholinergic effects of huperzine A: beyond inhibition of acetylcholinesterase.
Topics: Acetylcholinesterase; Alkaloids; Alzheimer Disease; Amyloid beta-Peptides; Animals; Cholinesterase I | 2008 |
East meets West in the search for Alzheimer's therapeutics - novel dimeric inhibitors from tacrine and huperzine A.
Topics: Alkaloids; Alzheimer Disease; Animals; Cholinesterase Inhibitors; Drugs, Chinese Herbal; Humans; Mod | 2007 |
An update on huperzine A as a treatment for Alzheimer's disease.
Topics: Alkaloids; Alzheimer Disease; Animals; Cholinesterase Inhibitors; Humans; Neuroprotective Agents; Se | 2008 |
[Progress of study on treatment of Alzheimer's disease with active ingredients of Chinese herbal medicines].
Topics: Alkaloids; Alzheimer Disease; Drugs, Chinese Herbal; Ginkgo biloba; Ginsenosides; Humans; Phytothera | 2008 |
Huperzine A for Alzheimer's disease.
Topics: Alkaloids; Alzheimer Disease; Cholinesterase Inhibitors; Humans; Randomized Controlled Trials as Top | 2008 |
Natural and synthetic Huperzine A: effect on cholinergic function in vitro and in vivo.
Topics: Acetylcholine; Acetylcholinesterase; Alkaloids; Alzheimer Disease; Animals; Brain; Cholinesterase In | 1993 |
Huperzine A (shuangyiping): a promising drug for Alzheimer's disease.
Topics: Alkaloids; Alzheimer Disease; Animals; Cholinesterase Inhibitors; Humans; Learning; Memory; Sesquite | 1996 |
Huperzine A--an interesting anticholinesterase compound from the Chinese herbal medicine.
Topics: Alkaloids; Alzheimer Disease; Animals; Cholinesterase Inhibitors; Humans; Sesquiterpenes | 1998 |
Molecular modelling and QSAR of reversible acetylcholines-terase inhibitors.
Topics: Alkaloids; Alzheimer Disease; Cholinesterase Inhibitors; Crystallography, X-Ray; Donepezil; Drug Des | 2000 |
Huperzine A, a potential therapeutic agent for treatment of Alzheimer's disease.
Topics: Acetylcholine; Alkaloids; Alzheimer Disease; Animals; Brain; Cholinesterase Inhibitors; Cholinestera | 2000 |
6 trials available for huperzine a and Alzheimer Disease
| Article | Year |
|---|---|
Huperzine-A response to cognitive impairment and task switching deficits in patients with Alzheimer's disease.
Topics: Aged; Alkaloids; Alzheimer Disease; Cholinesterase Inhibitors; Cognitive Dysfunction; Double-Blind M | 2019 |
Phase I study on the pharmacokinetics and tolerance of ZT-1, a prodrug of huperzine A, for the treatment of Alzheimer's disease.
Topics: Alkaloids; Alzheimer Disease; Cholinesterase Inhibitors; Cross-Over Studies; Double-Blind Method; Hu | 2013 |
A phase II trial of huperzine A in mild to moderate Alzheimer disease.
Topics: Aged; Aged, 80 and over; Alkaloids; Alzheimer Disease; Analysis of Variance; Apolipoproteins E; Dose | 2011 |
[Clinical efficacy and safety of huperzine Alpha in treatment of mild to moderate Alzheimer disease, a placebo-controlled, double-blind, randomized trial].
Topics: Aged; Aged, 80 and over; Alkaloids; Alzheimer Disease; Cholinesterase Inhibitors; Double-Blind Metho | 2002 |
Efficacy of tablet huperzine-A on memory, cognition, and behavior in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alkaloids; Alzheimer Disease; Behavior; Cholinesterase Inhibitors; Cognitio | 1995 |
Huperzine-A in capsules and tablets for treating patients with Alzheimer disease.
Topics: Aged; Aged, 80 and over; Alkaloids; Alzheimer Disease; Capsules; Cholinesterase Inhibitors; Double-B | 1999 |
61 other studies available for huperzine a and Alzheimer Disease
| Article | Year |
|---|---|
The Therapeutic Effects of Seven Lycopodium Compounds on Cell Models of Alzheimer's Disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid Precursor Protein Secretases; Animals; Aspartic Aci | 2022 |
Palladium-catalyzed synthesis and acetylcholinesterase inhibitory activity evaluation of 1-arylhuperzine A derivatives.
Topics: Acetylcholinesterase; Alzheimer Disease; Catalysis; Cholinesterase Inhibitors; Palladium | 2023 |
The Optimization Design Of Lactoferrin Loaded HupA Nanoemulsion For Targeted Drug Transport Via Intranasal Route.
Topics: Administration, Intranasal; Alkaloids; Alzheimer Disease; Animals; Biological Transport; Blood-Brain | 2019 |
Differential blockade by huperzine A and donepezil of sympathetic nicotinic acetylcholine receptor-mediated nitrergic neurogenic dilations in porcine basilar arteries.
Topics: Alkaloids; Alzheimer Disease; Animals; Basilar Artery; Brain Stem; Calcium; Cholinesterase Inhibitor | 2020 |
Combining antioxidant astaxantin and cholinesterase inhibitor huperzine A boosts neuroprotection.
Topics: Alkaloids; Alzheimer Disease; Animals; Antioxidants; Cholinesterase Inhibitors; Neuroprotective Agen | 2020 |
Five novel and highly efficient endophytic fungi isolated from Huperzia serrata expressing huperzine A for the treatment of Alzheimer's disease.
Topics: Alkaloids; Alzheimer Disease; Cholinesterase Inhibitors; Endophytes; Fusarium; Humans; Huperzia; Hyp | 2020 |
Pd-Catalyzed Direct Diversification of Natural Anti-Alzheimer's Disease Drug: Synthesis and Biological Evaluation of
Topics: Alkaloids; Alzheimer Disease; Blood-Brain Barrier; Catalysis; Cell Line, Tumor; Cholinesterase Inhib | 2021 |
Effects of Huperzin-A on the Beta-amyloid accumulation in the brain and skeletal muscle cells of a rat model for Alzheimer's disease.
Topics: Alkaloids; Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Cholinesterase Inhibitors; Dise | 2017 |
Intranasal delivery of Huperzine A to the brain using lactoferrin-conjugated N-trimethylated chitosan surface-modified PLGA nanoparticles for treatment of Alzheimer's disease.
Topics: Administration, Intranasal; Alkaloids; Alzheimer Disease; Animals; Brain; Chitosan; Drug Carriers; D | 2018 |
Discovery of Novel Acetylcholinesterase Inhibitors as Potential Candidates for the Treatment of Alzheimer's Disease.
Topics: Acetylcholinesterase; Alkaloids; Alzheimer Disease; Binding Sites; Cholinesterase Inhibitors; Databa | 2019 |
ABAD/17β-HSD10 reduction contributes to the protective mechanism of huperzine a on the cerebral mitochondrial function in APP/PS1 mice.
Topics: 3-Hydroxyacyl CoA Dehydrogenases; Alkaloids; Alzheimer Disease; Amyloid beta-Peptides; Animals; Brai | 2019 |
Quantitative proteomic analysis reveals the neuroprotective effects of huperzine A for amyloid beta treated neuroblastoma N2a cells.
Topics: Alkaloids; Alzheimer Disease; Amyloid beta-Peptides; Animals; Cell Death; Databases, Protein; Down-R | 2013 |
Free energy landscape for the binding process of Huperzine A to acetylcholinesterase.
Topics: Acetylcholinesterase; Alkaloids; Alzheimer Disease; Cholinesterase Inhibitors; Drug Discovery; Human | 2013 |
The use of borneol as an enhancer for targeting aprotinin-conjugated PEG-PLGA nanoparticles to the brain.
Topics: Alkaloids; Alzheimer Disease; Animals; Aprotinin; Behavior, Animal; Brain; Camphanes; Endothelial Ce | 2013 |
Reducing iron in the brain: a novel pharmacologic mechanism of huperzine A in the treatment of Alzheimer's disease.
Topics: ADAM Proteins; ADAM10 Protein; Alkaloids; Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precurso | 2014 |
Efficient strategy for maintaining and enhancing the huperzine A production of Shiraia sp. Slf14 through inducer elicitation.
Topics: Alkaloids; Alzheimer Disease; Ascomycota; Cell Extracts; Endophytes; Fermentation; Huperzia; Lysine; | 2014 |
Development of HuperTacrines as non-toxic, cholinesterase inhibitors for the potential treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alkaloids; Alzheimer Disease; Cholinesterase Inhibitors; Cholinesterases; Drug | 2015 |
Involvement of Intracellular and Mitochondrial Aβ in the Ameliorative Effects of Huperzine A against Oligomeric Aβ42-Induced Injury in Primary Rat Neurons.
Topics: Alkaloids; Alzheimer Disease; Amyloid beta-Peptides; Animals; Mitochondria; Neurons; Peptide Fragmen | 2015 |
Japanese Huperzia serrata extract and the constituent, huperzine A, ameliorate the scopolamine-induced cognitive impairment in mice.
Topics: Acetylcholinesterase; Alkaloids; Alzheimer Disease; Animals; Butyrylcholinesterase; Cholinesterase I | 2015 |
Huperzine A: A promising anticonvulsant, disease modifying, and memory enhancing treatment option in Alzheimer's disease.
Topics: Acetylcholinesterase; Alkaloids; Alzheimer Disease; Amyloid beta-Peptides; Animals; Animals, Genetic | 2017 |
A novel assay to determine acetylcholinesterase activity: The application potential for screening of drugs against Alzheimer's disease.
Topics: Acetylcholinesterase; Alkaloids; Alzheimer Disease; Animals; Brain Chemistry; Choline; Cholinesteras | 2017 |
In vitro production of huperzine A, a promising drug candidate for Alzheimer's disease.
Topics: Alkaloids; Alzheimer Disease; Huperzia; Molecular Structure; Sesquiterpenes; Tandem Mass Spectrometr | 2008 |
Huperzine A protects isolated rat brain mitochondria against beta-amyloid peptide.
Topics: Adenosine Triphosphate; Alkaloids; Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Cell De | 2009 |
Huperzine A activates Wnt/β-catenin signaling and enhances the nonamyloidogenic pathway in an Alzheimer transgenic mouse model.
Topics: Acetylcholinesterase; Alkaloids; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Prec | 2011 |
Microemulsion-based patch for transdermal delivery of huperzine A and ligustrazine phosphate in treatment of Alzheimer's disease.
Topics: Administration, Cutaneous; Alkaloids; Alzheimer Disease; Animals; Dose-Response Relationship, Drug; | 2012 |
Toxicological scoring of Alzheimer's disease drug huperzine in a guinea pig model.
Topics: Alanine Transaminase; Alkaloids; Alzheimer Disease; Animals; Apoptosis; Aspartate Aminotransferases; | 2012 |
Decreased accumulation of subcellular amyloid-β with improved mitochondrial function mediates the neuroprotective effect of huperzine A.
Topics: Acetylcholinesterase; Adenosine Triphosphate; Alkaloids; Alzheimer Disease; Amyloid beta-Peptides; A | 2012 |
Huprine X and huperzine A improve cognition and regulate some neurochemical processes related with Alzheimer's disease in triple transgenic mice (3xTg-AD).
Topics: Alkaloids; Alzheimer Disease; Aminoquinolines; Animals; Brain Chemistry; Cerebral Cortex; Cognition | 2013 |
New insights into huperzine A for the treatment of Alzheimer's disease.
Topics: Alkaloids; Alzheimer Disease; Animals; Cholinesterase Inhibitors; Drug Delivery Systems; Drugs, Chin | 2012 |
Huperzia quadrifariata and Huperzia reflexa alkaloids inhibit acetylcholinesterase activity in vivo in mice brain.
Topics: Acetylcholinesterase; Alkaloids; Alzheimer Disease; Animals; Brain; Cerebral Cortex; Cholinesterase | 2012 |
Bis(9)-(-)-nor-meptazinol as a novel dual-binding AChEI potently ameliorates scopolamine-induced cognitive deficits in mice.
Topics: Acetylcholinesterase; Alkaloids; Alzheimer Disease; Animals; Brain; Cholinesterase Inhibitors; Cogni | 2013 |
New nicotinic analogue ZY-1 enhances cognitive functions in a transgenic mice model of Alzheimer's disease.
Topics: Alkaloids; Alzheimer Disease; Animals; Cell Line; Escape Reaction; Maze Learning; Mice; Mice, Transg | 2013 |
Investigating the antioxidant and acetylcholinesterase inhibition activities of Gossypium herbaceam.
Topics: Alkaloids; Alzheimer Disease; Animals; Benzothiazoles; Biphenyl Compounds; Cell Survival; Cholineste | 2013 |
[Studies on analogues of huperzine A for treatment of senile dementia. VI. Asymmetric total synthesis of 14-nor-huperzine A and its inhibitory activity of acetylcholinesterase].
Topics: Acetylcholinesterase; Alkaloids; Alzheimer Disease; Animals; Cholinesterase Inhibitors; Erythrocyte | 2003 |
Comparative effects of huperzine A, donepezil and rivastigmine on cortical acetylcholine level and acetylcholinesterase activity in rats.
Topics: Acetylcholine; Acetylcholinesterase; Alkaloids; Alzheimer Disease; Animals; Brain Chemistry; Carbama | 2004 |
(+/-)-huprine Y, (-)-huperzine A and tacrine do not show neuroprotective properties in an apoptotic model of neuronal cytoskeletal alteration.
Topics: Alkaloids; Alzheimer Disease; Aminoquinolines; Animals; Animals, Newborn; Apoptosis; Cerebellum; Cho | 2004 |
Preparation and in vitro and in vivo release studies of Huperzine A loaded microspheres for the treatment of Alzheimer's disease.
Topics: Alkaloids; Alzheimer Disease; Animals; Cholinesterase Inhibitors; Desiccation; Dogs; Drug Compoundin | 2005 |
Effects of formulation factors on encapsulation efficiency and release behaviour in vitro of huperzine A-PLGA microspheres.
Topics: Alkaloids; Alzheimer Disease; Delayed-Action Preparations; Drug Compounding; Humans; Lactic Acid; Mi | 2005 |
Position statement of the American Association for Geriatric Psychiatry regarding principles of care for patients with dementia resulting from Alzheimer disease.
Topics: Aged; Alkaloids; Alzheimer Disease; Brain; Caregivers; Cholinesterase Inhibitors; Cognition Disorder | 2006 |
Controlled release of huperzine A from biodegradable microspheres: In vitro and in vivo studies.
Topics: Acetylcholinesterase; Alkaloids; Alzheimer Disease; Animals; Calorimetry, Differential Scanning; Cer | 2007 |
Editorial: natural products chemistry in China.
Topics: Alkaloids; Alzheimer Disease; Artemisinins; Biological Products; Malaria; Medicine, Chinese Traditio | 2006 |
Neuroprotective effects of huperzine A: new therapeutic targets for neurodegenerative disease.
Topics: Alkaloids; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Apoptosis; Cholinesterase Inh | 2006 |
Sensitivity of butyrylcholinesterase knockout mice to (--)-huperzine A and donepezil suggests humans with butyrylcholinesterase deficiency may not tolerate these Alzheimer's disease drugs and indicates butyrylcholinesterase function in neurotransmission.
Topics: Acetylcholine; Acetylcholinesterase; Alkaloids; Alzheimer Disease; Animals; Butyrylcholinesterase; C | 2007 |
The effects of Liuwei Dihuang decoction on the gene expression in the hippocampus of senescence-accelerated mouse.
Topics: Aging; Alkaloids; Alzheimer Disease; Animals; Cholinesterase Inhibitors; DNA, Complementary; Drugs, | 2007 |
Huperzine A regulates amyloid precursor protein processing via protein kinase C and mitogen-activated protein kinase pathways in neuroblastoma SK-N-SH cells over-expressing wild type human amyloid precursor protein 695.
Topics: ADAM Proteins; ADAM10 Protein; ADAM17 Protein; Alkaloids; Alzheimer Disease; Amyloid beta-Peptides; | 2007 |
Pharmacokinetics of Huperzine A after transdermal and oral administration in beagle dogs.
Topics: Administration, Cutaneous; Administration, Oral; Alkaloids; Alzheimer Disease; Animals; Cholinestera | 2008 |
Synthesis and evaluation of 5-amino-5,6,7,8-tetrahydroquinolinones as potential agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alkaloids; Alzheimer Disease; Aminoquinolines; Animals; Cholinesterase Inhibit | 1995 |
Old Chinese herbal medicine used for fever yields possible new Alzheimer disease therapy.
Topics: Alkaloids; Alzheimer Disease; Animals; Cholinesterase Inhibitors; Clinical Trials as Topic; Drug Des | 1997 |
Synthesis and evaluation of tacrine-huperzine A hybrids as acetylcholinesterase inhibitors of potential interest for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alkaloids; Alzheimer Disease; Animals; Cattle; Cholinesterase Inhibitors; Magn | 1998 |
Treatment of Alzheimer's disease.
Topics: Alkaloids; Alzheimer Disease; Cholinesterase Inhibitors; Drug Therapy, Combination; Humans; Sesquite | 2000 |
Huperzine A and tacrine attenuate beta-amyloid peptide-induced oxidative injury.
Topics: Alkaloids; Alzheimer Disease; Amyloid beta-Peptides; Animals; Catalase; Cell Survival; Cells, Cultur | 2000 |
Similar potency of the enantiomers of huperzine A in inhibition of [(3)H]dizocilpine (MK-801) binding in rat cerebral cortex.
Topics: Alkaloids; Alzheimer Disease; Animals; Binding Sites; Cerebral Cortex; Cholinesterase Inhibitors; Di | 2000 |
New tacrine-huperzine A hybrids (huprines): highly potent tight-binding acetylcholinesterase inhibitors of interest for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alkaloids; Alzheimer Disease; Animals; Bridged Bicyclo Compounds; Butyrylcholi | 2000 |
Huperzine A and donepezil protect rat pheochromocytoma cells against oxygen-glucose deprivation.
Topics: Alkaloids; Alzheimer Disease; Animals; Cell Size; Cell Survival; Cholinesterase Inhibitors; Donepezi | 2001 |
Huperzine A, a nootropic alkaloid, inhibits N-methyl-D-aspartate-induced current in rat dissociated hippocampal neurons.
Topics: Alkaloids; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Alzheimer Disease; Animals; Cel | 2001 |
Huperzine A attenuates amyloid beta-peptide fragment 25-35-induced apoptosis in rat cortical neurons via inhibiting reactive oxygen species formation and caspase-3 activation.
Topics: Alkaloids; Alzheimer Disease; Amyloid beta-Peptides; Animals; Animals, Newborn; Apoptosis; Caspase 3 | 2002 |
Stereoselectivities of enantiomers of huperzine A in protection against beta-amyloid(25-35)-induced injury in PC12 and NG108-15 cells and cholinesterase inhibition in mice.
Topics: Acetylcholine; Alkaloids; Alzheimer Disease; Amyloid beta-Peptides; Animals; Cerebral Cortex; Cholin | 2002 |
Spermidine antagonizes the inhibitory effect of huperzine A on [3H]dizocilpine (MK-801) binding in synaptic membrane of rat cerebral cortex.
Topics: Alkaloids; Alzheimer Disease; Animals; Binding Sites; Binding, Competitive; Cerebral Cortex; Choline | 2002 |
Huperzine A, a nootropic agent, inhibits fast transient potassium current in rat dissociated hippocampal neurons.
Topics: Acetylcholine; Alkaloids; Alzheimer Disease; Animals; Animals, Newborn; Cells, Cultured; Cholinester | 2002 |
Huperzine A--a potent acetylcholinesterase inhibitor of use in the treatment of Alzheimer's disease.
Topics: Alkaloids; Alzheimer Disease; Chemical Phenomena; Chemistry, Physical; Cholinesterase Inhibitors; Cr | 1991 |
Dietary n-3 polyunsaturated fatty acid depletion activates caspases and decreases NMDA receptors in the brain of a transgenic mouse model of Alzheimer's disease.
Topics: Alkaloids; Alzheimer Disease; Amyloid beta-Protein Precursor; Analysis of Variance; Animals; bcl-Ass | 2005 |